{"id":"oral-antihyperglycemics","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lactic acidosis (biguanides)"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a broad drug class rather than a single agent, encompassing multiple mechanistic approaches to glycemic control. Eli Lilly's oral antihyperglycemic portfolio includes agents such as sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, and SGLT2 inhibitors, each targeting different pathways in glucose homeostasis. The specific mechanism depends on the individual compound within the class.","oneSentence":"Oral antihyperglycemics lower blood glucose levels through various mechanisms including insulin secretion enhancement, insulin sensitivity improvement, or glucose absorption reduction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:35.428Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06671587","phase":"PHASE4","title":"iGlarLixi CGM Study in Chinese T2D Individuals After OADs","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-10","conditions":"Type 2 Diabetes (T2D)","enrollment":678},{"nctId":"NCT07472725","phase":"PHASE2","title":"A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-04","conditions":"Diabetes Mellitus, Type 2","enrollment":90},{"nctId":"NCT07467967","phase":"NA","title":"Impact of Date Consumption on Metabolic Control and Oxidative Stress in Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"University Tunis El Manar","startDate":"2026-07-15","conditions":"Diabete Type 2","enrollment":130},{"nctId":"NCT07436182","phase":"PHASE4","title":"Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2026-03-01","conditions":"Mitochondria, Metformin","enrollment":176},{"nctId":"NCT07436663","phase":"PHASE4","title":"Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT03905941","phase":"EARLY_PHASE1","title":"Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age","status":"WITHDRAWN","sponsor":"University of Virginia","startDate":"2021-08-23","conditions":"Polycystic Ovary Syndrome","enrollment":""},{"nctId":"NCT07173712","phase":"PHASE4","title":"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Yanbing Li","startDate":"2026-03-15","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":"Chronic Kidney Diseases, MAFLD","enrollment":90},{"nctId":"NCT07387003","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2026-03-20","conditions":"Type 2 Diabetes (T2DM)","enrollment":300},{"nctId":"NCT07377448","phase":"","title":"Insulin Use and Respiratory Muscle Strength in Type 2 Diabetes","status":"COMPLETED","sponsor":"Izmir Bakircay University","startDate":"2025-01-02","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 2 Treated With Insulin","enrollment":70},{"nctId":"NCT02648009","phase":"PHASE1","title":"Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2016-04","conditions":"Hypertension, Hypertrophy","enrollment":112},{"nctId":"NCT07303556","phase":"NA","title":"Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nazarbayev University","startDate":"2024-12-18","conditions":"Heart Failure, Diabete Type 2, Arterial Hypertension","enrollment":120},{"nctId":"NCT07374328","phase":"PHASE1, PHASE2","title":"Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-06-01","conditions":"Type 2 Diabetes","enrollment":240},{"nctId":"NCT06881264","phase":"PHASE3","title":"A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-04-30","conditions":"Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs","enrollment":401},{"nctId":"NCT07365592","phase":"PHASE1, PHASE2","title":"Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":"Colorectal Cancer","enrollment":138},{"nctId":"NCT01239550","phase":"NA","title":"Insulin Detemir in Obesity Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University","startDate":"2011-04","conditions":"Diabetes, Obesity","enrollment":240},{"nctId":"NCT05164263","phase":"PHASE4","title":"Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study","status":"RECRUITING","sponsor":"Getz Pharma","startDate":"2021-04-01","conditions":"Type II Diabetes Mellitus, Efficacy, Self, Safety Issues","enrollment":2000},{"nctId":"NCT07063797","phase":"NA","title":"Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-02-01","conditions":"Type 2 Diabetes, Osteoporosis, Fractures","enrollment":358},{"nctId":"NCT07351786","phase":"","title":"Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy","status":"RECRUITING","sponsor":"Sara A Belal","startDate":"2025-08-01","conditions":"Diabetes (DM), Retinopathy, Diabetic, Diabetic Retinopathy (DR)","enrollment":70},{"nctId":"NCT06149793","phase":"PHASE2, PHASE3","title":"SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Minnesota","startDate":"2024-01-08","conditions":"Cystic Fibrosis-related Diabetes, Cystic Fibrosis","enrollment":8},{"nctId":"NCT07340320","phase":"PHASE2","title":"A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus","status":"NOT_YET_RECRUITING","sponsor":"Corxel Pharmaceuticals","startDate":"2026-02-05","conditions":"Type II Diabetes Mellitus","enrollment":240},{"nctId":"NCT06871761","phase":"PHASE3","title":"A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-05-08","conditions":"Adult Patients With Type 2 Diabetes","enrollment":393},{"nctId":"NCT07295223","phase":"PHASE3","title":"Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-12-30","conditions":"Acute Myocardial Infarction With ST Elevation","enrollment":44},{"nctId":"NCT01301833","phase":"PHASE3","title":"Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-02","conditions":"Type 2 Diabetes Mellitus","enrollment":462},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT06507475","phase":"","title":"Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-09-07","conditions":"Diabetes Mellitus, Type 2","enrollment":209},{"nctId":"NCT05749679","phase":"NA","title":"Prevention of Renal Failure in People Followed for Type 2 Diabetes in General Practice","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2026-07","conditions":"Renal Insufficiency and Diabetes Mellitus","enrollment":360},{"nctId":"NCT07172971","phase":"PHASE1","title":"Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Larry W. Markham","startDate":"2026-02-01","conditions":"Duchenne Muscular Dystrophy (DMD)","enrollment":10},{"nctId":"NCT07294495","phase":"NA","title":"Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR","status":"NOT_YET_RECRUITING","sponsor":"Shanghai East Hospital","startDate":"2026-01-07","conditions":"HCM - Hypertrophic Cardiomyopathy","enrollment":150},{"nctId":"NCT07057479","phase":"PHASE3","title":"Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""},{"nctId":"NCT07279909","phase":"PHASE3","title":"Phase-III Clinical Studies on Poly Herbal Anti-Diabetic Formulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hamdard University","startDate":"2024-03-09","conditions":"Diabetes Type 2, Diabetes Mellitus, Experimental, HbA1c","enrollment":500},{"nctId":"NCT07265037","phase":"NA","title":"Integrated TCM - Western Medicine Strategy for Long - Distance Diabetes Management","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-11-01","conditions":"Diabetes Mellitus, Type 2, Integrated Traditional Chinese Medicine and Western Medicine, Telemedicine","enrollment":10000},{"nctId":"NCT07239011","phase":"PHASE1, PHASE2","title":"Dapagliflozin in Depression","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-01","conditions":"Depression","enrollment":60},{"nctId":"NCT07244003","phase":"PHASE4","title":"Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-03-29","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":430},{"nctId":"NCT07055386","phase":"PHASE2","title":"A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-08-07","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":90},{"nctId":"NCT07018453","phase":"PHASE2","title":"A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-07-16","conditions":"Type 2 Diabetes Mellitus","enrollment":173},{"nctId":"NCT04742751","phase":"PHASE2","title":"An Open-Label Pilot Intervention Trial to Prevent Diabetes in Prediabetic Adult Survivors of Childhood Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-03-02","conditions":"PreDiabetes, Adult Children","enrollment":96},{"nctId":"NCT07209527","phase":"EARLY_PHASE1","title":"Truway Diagnostic Tools in Primary Care","status":"ENROLLING_BY_INVITATION","sponsor":"Truway Health, Inc.","startDate":"2025-10-01","conditions":"Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension","enrollment":200},{"nctId":"NCT07207694","phase":"NA","title":"WhatsApp-Based Education Program for Stroke Patients","status":"NOT_YET_RECRUITING","sponsor":"Gaziler Physical Medicine and Rehabilitation Education and Research Hospital","startDate":"2025-10-15","conditions":"Type 2 Diabetes Mellitus (T2DM), Stroke","enrollment":84},{"nctId":"NCT06813274","phase":"PHASE2","title":"Multicenter RCT of Eye-Brain Imaging in Diabetes Neurovascular Coupling","status":"NOT_YET_RECRUITING","sponsor":"Hejiang Ye","startDate":"2026-01-01","conditions":"Diabetes Mellitus, Diabetic Retinopathy, Cognitive Impairment","enrollment":160},{"nctId":"NCT04826692","phase":"PHASE3","title":"TEsting METformin Against Cognitive Decline in HD","status":"COMPLETED","sponsor":"Instituto de Investigacion Sanitaria La Fe","startDate":"2022-04-11","conditions":"Huntington Disease","enrollment":60},{"nctId":"NCT01471808","phase":"PHASE4","title":"Effects of Different Early Intensive Therapies on Long-term β-cell Function","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2011-10","conditions":"Diabetes Mellitus, Type 2","enrollment":264},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT04980027","phase":"PHASE4","title":"Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-06-07","conditions":"Type 2 Diabetes Mellitus","enrollment":228},{"nctId":"NCT02710448","phase":"PHASE2","title":"May Metformin be Used in Renal Failure?","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2012-06","conditions":"Renal Disorder Associated With Type II Diabetes Mellitus","enrollment":82},{"nctId":"NCT04198857","phase":"NA","title":"Development and Testing of a Mobile Health Application for Management of Gestational Diabetes","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2021-10-18","conditions":"Diabetes, Gestational, Telemedicine","enrollment":220},{"nctId":"NCT03608163","phase":"PHASE4","title":"Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2019-01-08","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness","enrollment":4},{"nctId":"NCT07139548","phase":"PHASE3","title":"A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2025-08-31","conditions":"T2DM","enrollment":600},{"nctId":"NCT07121088","phase":"PHASE4","title":"Traditional Chinese Medicine Intervention for Ischemic Cerebrovascular Disease and Diabetes Mellitus: An Efficacy Comparative Study","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2025-08-31","conditions":"Ischemic Cerebral Infarction, Diabetes Mellitus","enrollment":3666},{"nctId":"NCT06090890","phase":"PHASE4","title":"Anti-inflammatory Therapy for Recurrent In-stent Restenosis","status":"RECRUITING","sponsor":"Fu Wai Hospital, Beijing, China","startDate":"2023-10-30","conditions":"In-stent Restenosis","enrollment":252},{"nctId":"NCT07074379","phase":"NA","title":"Endotherapy and/or Extracorporeal Shockwave Lithotripsy for Painless Chronic Pancreatitis","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-07-21","conditions":"Painless Chronic Pancreatitis","enrollment":126},{"nctId":"NCT06649773","phase":"PHASE3","title":"The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-10-25","conditions":"Type 2 Diabetes","enrollment":137},{"nctId":"NCT07088523","phase":"PHASE4","title":"Traditional Chinese Medicine Intervention for Ischemic Cardiovascular Disease Comorbid With Diabetes Mellitus: An Efficacy Comparative Study","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2025-07-31","conditions":"Diabete Mellitus, Ischemic Cardiovascular Disease","enrollment":4205},{"nctId":"NCT06846138","phase":"NA","title":"Enhancing the Efficacy and Tolerability of Metformin by add-on Polyherbal Formulation: a Gut Microbiome Study","status":"ENROLLING_BY_INVITATION","sponsor":"Pauls Stradins Clinical University Hospital","startDate":"2025-03-01","conditions":"Diabetes Mellitus Type 2","enrollment":66},{"nctId":"NCT06010004","phase":"PHASE3","title":"A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-09-28","conditions":"Type 2 Diabetes","enrollment":466},{"nctId":"NCT07049601","phase":"NA","title":"THE Effect of Tight Glycemic Control on Microvascular Complications in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-05-11","conditions":"Diabetes Mellitus","enrollment":80},{"nctId":"NCT06562582","phase":"PHASE4","title":"STunning in Acute Myocardial Infarction - BAS","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2025-01-06","conditions":"Myocardial Infarct","enrollment":120},{"nctId":"NCT06995339","phase":"PHASE2","title":"Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2025-05-30","conditions":"Gout","enrollment":60},{"nctId":"NCT06476730","phase":"NA","title":"Telerehabilitation Exercise: Effects on Maternal Psychological Health and Delivery Outcomes","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2024-07-01","conditions":"Gestational Diabetes Mellitus in Pregnancy, Gestational Diabetes, Maternal Psychological Distress","enrollment":62},{"nctId":"NCT06480292","phase":"NA","title":"Telerehabilitation Exercise: Effects on Maternal Quality of Life, Fetal and Neonatal Health.","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2024-07-01","conditions":"Gestational Diabetes Mellitus in Pregnancy","enrollment":68},{"nctId":"NCT06452017","phase":"NA","title":"Effects of Telerehabilitation Exercise Program on Maternal Glycemic Control","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2024-06-10","conditions":"Gestational Diabetes Mellitus in Pregnancy","enrollment":70},{"nctId":"NCT04841096","phase":"PHASE3","title":"Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2023-03-21","conditions":"Type 2 Diabetes","enrollment":162},{"nctId":"NCT06719661","phase":"NA","title":"The Impact of Clinical Pharmacist Intervention and Dapagliflozin as Add-On Therapy in the Management of Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"University of Sulaimani","startDate":"2024-12-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":138},{"nctId":"NCT01242202","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":"Type 2 Diabetes Mellitus","enrollment":113},{"nctId":"NCT01242228","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":"Type 2 Diabetes Mellitus","enrollment":106},{"nctId":"NCT06668389","phase":"PHASE4","title":"Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-05-12","conditions":"Congenital Heart Disease, Repaired Tetralogy of Fallot (rTOF), Pulmonary Regurgitation","enrollment":106},{"nctId":"NCT06932874","phase":"PHASE4","title":"Metformin Hydrochloride Sustained-release Tablets (Ⅲ) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-03-04","conditions":"Atherosclerotic Heart Disease, Type 2 Diabetes","enrollment":356},{"nctId":"NCT06929169","phase":"PHASE2","title":"Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study","status":"RECRUITING","sponsor":"Maximo Agustin Schiavone","startDate":"2025-05","conditions":"Chronic Kidney Disease Requiring Hemodialysis","enrollment":80},{"nctId":"NCT06916871","phase":"NA","title":"Optimizing Care for Diabetic Patients in Hospitalized Rehabilitation Through Structured Education","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Liege","startDate":"2025-04-07","conditions":"Diabetes Mellitus Self Management Education","enrollment":100},{"nctId":"NCT06913101","phase":"NA","title":"Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"PNS Hafeez - Naval Hospital","startDate":"2024-11-15","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":102},{"nctId":"NCT04662723","phase":"PHASE4","title":"Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.","status":"RECRUITING","sponsor":"Fondazione Schena","startDate":"2023-05-01","conditions":"Glomerulonephritis, Immunoglobulin A Nephropathy","enrollment":878},{"nctId":"NCT06889909","phase":"NA","title":"Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lahore General Hospital","startDate":"2024-12-15","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":102},{"nctId":"NCT04809311","phase":"","title":"Remote Study Collecting Blood Glucose Values and Activity Data in Patients With Type 2 Diabetes on Different Treatments","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-04-30","conditions":"Diabetes Mellitus, Type 2","enrollment":156},{"nctId":"NCT06862180","phase":"NA","title":"Effect of Meal Replacement Therapy on Glucose Control and Metabolic Parameters in Patients With Uncontrolled Diabetes","status":"RECRUITING","sponsor":"Hospital Universiti Sains Malaysia","startDate":"2024-11-01","conditions":"Diabetes Mellitus, Type 2","enrollment":108},{"nctId":"NCT04116203","phase":"PHASE1","title":"Dietary Fish Oil Intervention in Polycystic Ovary Syndrome (PCOS)","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2016-06-30","conditions":"Polycystic Ovary Syndrome, Lipid Metabolism Disorders","enrollment":52},{"nctId":"NCT04409795","phase":"PHASE2, PHASE3","title":"Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study","status":"COMPLETED","sponsor":"Joslin Diabetes Center","startDate":"2021-08-26","conditions":"Type 1 Diabetes, Monogenic Diabetes","enrollment":3},{"nctId":"NCT05699408","phase":"PHASE3","title":"To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-03-31","conditions":"Type 2 Diabetes","enrollment":513},{"nctId":"NCT06825182","phase":"PHASE3","title":"Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-11-07","conditions":"Type 2 Diabetes Mellitus","enrollment":1000},{"nctId":"NCT04114136","phase":"PHASE2","title":"Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2020-09-14","conditions":"Melanoma, NSCLC, Hepatocellular Carcinoma","enrollment":72},{"nctId":"NCT06479629","phase":"PHASE4","title":"The Effect of Piracetam on Diabetic Peripheral Neuropathy Patients","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2025-02-10","conditions":"Diabetic Peripheral Neuropathy","enrollment":60},{"nctId":"NCT06202079","phase":"PHASE2","title":"A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2023-08-11","conditions":"Diabetes Mellitus, Type 2","enrollment":179},{"nctId":"NCT04275713","phase":"PHASE2","title":"Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2020-05-22","conditions":"Cervical Cancer","enrollment":41},{"nctId":"NCT06199505","phase":"PHASE2","title":"A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2023-11-21","conditions":"Type 2 Diabetes","enrollment":153},{"nctId":"NCT05055804","phase":"NA","title":"The ELG Analysis of Glucose a Correlational to Blood Glucose Assay","status":"ENROLLING_BY_INVITATION","sponsor":"XP Technology, LLC","startDate":"2021-08-11","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT06125587","phase":"PHASE2, PHASE3","title":"Chiglitazar/Metformin in Non-obese Women With PCOS","status":"COMPLETED","sponsor":"Shengjing Hospital","startDate":"2023-11-15","conditions":"Polycystic Ovary Syndrome, Chiglitazar, Metformin","enrollment":55},{"nctId":"NCT06746610","phase":"NA","title":"Screening and Molecular Diagnosis-based Individualized Precision Management of Monogenic Diabetes","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2022-08-01","conditions":"Monogenic Diabetes","enrollment":2000},{"nctId":"NCT06725238","phase":"","title":"Acute-to-chronic Glycemic Ratio (ACGR) is a Marker of DFUs .","status":"COMPLETED","sponsor":"University of Diyala","startDate":"2024-05-01","conditions":"Diabetic Foot Ulcer (DFU)","enrollment":80},{"nctId":"NCT06005142","phase":"NA","title":"Therapeutic Intervention of Eriomin Associated with Metformin in the Control of Hyperglycemia in Pre-Diabetic Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thais Cesar","startDate":"2024-01-15","conditions":"Pre-diabetes","enrollment":80},{"nctId":"NCT04813146","phase":"NA","title":"Role of Synchronized Lifestyle Modification Program on Diabetic Neuropathy Taking Oral Hypoglycemics","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2021-02-05","conditions":"Diabetic Neuropathies","enrollment":216},{"nctId":"NCT01672762","phase":"PHASE3","title":"A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-05-25","conditions":"Type 2 Diabetes Mellitus","enrollment":174},{"nctId":"NCT06670417","phase":"NA","title":"Low-level Laser Therapy Versus Offloading Exercises on Foot Ulcer Healing in Patients with Type 2 Diabetes","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2024-11-30","conditions":"Diabetic Foot Ulcer (DFU)","enrollment":60},{"nctId":"NCT06613854","phase":"PHASE4","title":"Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes","status":"RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2024-10-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":90},{"nctId":"NCT03418779","phase":"PHASE2, PHASE3","title":"Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2019-07-04","conditions":"IgA Nephropathy at High Risk of Developing ESRD","enrollment":60},{"nctId":"NCT04530981","phase":"PHASE1","title":"A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST","status":"COMPLETED","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2021-09-22","conditions":"GIST - Gastrointestinal Stromal Tumor","enrollment":13},{"nctId":"NCT04342819","phase":"PHASE2, PHASE3","title":"The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.","status":"COMPLETED","sponsor":"The University of The West Indies","startDate":"2020-01-01","conditions":"Platelet Dysfunction Due to Drugs","enrollment":25},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","enrollment":200},{"nctId":"NCT06333080","phase":"","title":"The Effect of Adherence to Oral Semaglutide on Glycaemic Control in People With Type 2 Diabetes Treated With Metformin","status":"RECRUITING","sponsor":"Aalborg University Hospital","startDate":"2023-11-01","conditions":"Diabetes Mellitus, Type 2","enrollment":20},{"nctId":"NCT06520995","phase":"NA","title":"Elderly Patients With Type 2 Diabetes and Cognitive Exercises","status":"RECRUITING","sponsor":"Istanbul University - Cerrahpasa","startDate":"2024-04-01","conditions":"Cognitive Impairment, Diabetes Mellitus, Type 2, Diabetes Complications","enrollment":90},{"nctId":"NCT06517602","phase":"NA","title":"Effect of Moringa Oleifera Leaves on Glycemic Control of Women With Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Milan","startDate":"2019-11-07","conditions":"Type 2 Diabetes","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oral antihyperglycemics","genericName":"Oral antihyperglycemics","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oral antihyperglycemics lower blood glucose levels through various mechanisms including insulin secretion enhancement, insulin sensitivity improvement, or glucose absorption reduction. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}